Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 01, 2026 07:00 ET | Source: Ocular Therapeutix, Inc.

Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April

BEDFORD, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today...
April 01, 2026 07:00 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting

BOSTON and SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and...
April 01, 2026 06:45 ET | Source: KALA BIO, Inc.

Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities

TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio Inc. (NASDAQ: KALA), a clinical-stage biopharmaceutical company at the forefront of artificial intelligence and cell and gene therapy innovation,...
April 01, 2026 02:40 ET | Source: AskBio Inc. (AskBio)

AskBio Announces Completion of Enrollment in Phase 2 Clinical Trial of AB-1002 Investigational Gene Therapy for Heart Failure

Durham, N.C., April 01, 2026 (GLOBE NEWSWIRE) -- Final participant randomized in the GenePHIT Phase 2 clinical trial assessing safety and efficacy of AB-1002 for adults with non-ischemic...
March 31, 2026 22:39 ET | Source: Base Carbon Inc.

Base Carbon Reports Year End 2025 Operating and Financial Results

TORONTO, March 31, 2026 (GLOBE NEWSWIRE) -- Base Carbon Inc. (Cboe CA: BCBN) (OTCQX: BCBNF) with operations through its wholly-owned subsidiary, Base Carbon Capital Partners Corp. (“BCCPC”,...
March 31, 2026 16:49 ET | Source: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG). Such investors are advised to...
March 31, 2026 16:30 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics CEO Issues Letter to Shareholders

Advancing Zervimesine (CT1812) towards late-stage trials for dementia with Lewy bodies (DLB) psychosis Fully funded $80 million Phase 2 START trial readout expected in the second half of 2027 ...
March 31, 2026 16:15 ET | Source: Nanobiotix S.A.

NANOBIOTIX fait le point sur ses activités et publie ses résultats financiers de l’exercice 2025

Le programme de développement global de JNJ-1900 (NBTXR3) a progressé comme prévu, ouvrant la voie à une opportunité d’adresser l’un des plus grands marchés encore inexploités en oncologie grâce aux...
March 31, 2026 16:15 ET | Source: Nanobiotix S.A.

NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results

Global development program for JNJ-1900 (NBTXR3) proceeded as planned, building toward opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck...
March 31, 2026 16:06 ET | Source: BioAtla, Inc.

BioAtla Announces Share Consolidation

SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ: BCAB or the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic...